English
简体中文
Total: £ 56.28
Published Date: 2026-04-10 | Pages: 103 | Tables: 104 | Pharma & Healthcare
The global Intravitreal Injectable market was valued at US$ 19020 million in 2025 and is anticipated to reach US$ 30530 million by 2032, at a CAGR of 7.1% from 2026 to 2032.
Intravitreal injectables are sterile pharmaceutical formulations administered directly into the vitreous humor of the eye using a fine needle. This route of administration allows for targeted delivery of medications—such as anti-VEGF agents, corticosteroids, or antibiotics—into the posterior segment of the eye, ensuring high local drug concentrations while minimizing systemic exposure. Intravitreal injections are commonly used to treat retinal diseases including age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and infectious endophthalmitis.
The global intravitreal injectable market has experienced steady growth in recent years, driven primarily by the rising prevalence of retinal disorders such as macular edema, age-related macular degeneration (AMD), and retinal vein occlusion (RVO). North America currently dominates the global market, holding a share of more than 50%, followed by Europe and Asia-Pacific, each with shares exceeding 40%.
In terms of drug types, anti-VEGF (vascular endothelial growth factor) therapies represent the largest and most significant market segment, contributing to over 85% of total market revenue. These agents are highly effective in inhibiting abnormal blood vessel growth in the retina, making them the standard of care for diseases like AMD and diabetic macular edema (DME). Other therapeutic classes such as corticosteroids and antibiotics play smaller roles, typically in more specialized or adjunctive treatment scenarios.
The largest clinical application of intravitreal injectables is for macular edema, which continues to see a rise in incidence linked to diabetes and aging populations worldwide. Macular degeneration and RVO are also major contributors to demand, reinforcing the importance of targeted ophthalmic treatments. The increase in awareness, earlier diagnosis, and improved accessibility to eye care services are further driving market expansion across both developed and emerging regions.
Looking ahead, the market is expected to grow steadily due to increasing disease burden and product innovation. Notably, new players such as Astellas Pharma have begun entering the market, signaling a shift toward broader competition and possibly next-generation therapies with extended efficacy and dosing intervals. Advances in drug delivery systems, longer-acting formulations, and biosimilars are expected to further shape the landscape and offer new growth opportunities.
This report delivers a comprehensive overview of the global Intravitreal Injectable market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Intravitreal Injectable. The Intravitreal Injectable market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Intravitreal Injectable market comprehensively. Regional market sizes by Drug, by Disease, by Formulation Type, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Intravitreal Injectable manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Drug, by Disease, and by region.
Market Segmentation
By Company
Regeneron Pharmaceuticals
Bausch & Lomb
Novartis
AbbVie (Allergan)
Alimera Sciences
Roche
Bristol-Myers Squibb
Bayer
Bausch + Lomb
EyePoint Pharmaceuticals
Segment by Drug
Anti-VEGF Agents
Corticosteroids / Steroid Implants
Thrombolytic / Enzymatic Agents
Others
Segment by Formulation Type
Solution for Intravitreal Injection
Suspension for Intravitreal Injection
Others
Segment by Duration of Action
Short-acting (4–6 weeks)
Medium-acting (8–12 weeks)
Long-acting (> 6 months)
Segment by Disease
Macular Degeneration
Macular Edema
Uveitis
Retinal Vein Occlusion
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Drug, by Disease, by Formulation Type, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Intravitreal Injectable companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Drug, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Disease, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Drug
1.2.1 Global Intravitreal Injectable Market Size Growth Rate by Drug: 2021 vs 2025 vs 2032
1.2.2 Anti-VEGF Agents
1.2.3 Corticosteroids / Steroid Implants
1.2.4 Thrombolytic / Enzymatic Agents
1.2.5 Others
1.3 Market by Formulation Type
1.3.1 Global Intravitreal Injectable Market Size Growth Rate by Formulation Type: 2021 vs 2025 vs 2032
1.3.2 Solution for Intravitreal Injection
1.3.3 Suspension for Intravitreal Injection
1.3.4 Others
1.4 Market by Duration of Action
1.4.1 Global Intravitreal Injectable Market Size Growth Rate by Duration of Action: 2021 vs 2025 vs 2032
1.4.2 Short-acting (4–6 weeks)
1.4.3 Medium-acting (8–12 weeks)
1.4.4 Long-acting (> 6 months)
1.5 Market by Disease
1.5.1 Global Intravitreal Injectable Market Growth by Disease: 2021 vs 2025 vs 2032
1.5.2 Macular Degeneration
1.5.3 Macular Edema
1.5.4 Uveitis
1.5.5 Retinal Vein Occlusion
1.5.6 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends
2.1 Global Intravitreal Injectable Market Perspective (2021–2032)
2.2 Global Intravitreal Injectable Growth Trends by Region
2.2.1 Global Intravitreal Injectable Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Intravitreal Injectable Historic Market Size by Region (2021–2026)
2.2.3 Intravitreal Injectable Forecasted Market Size by Region (2027–2032)
2.3 Intravitreal Injectable Market Dynamics
2.3.1 Intravitreal Injectable Industry Trends
2.3.2 Intravitreal Injectable Market Drivers
2.3.3 Intravitreal Injectable Market Challenges
2.3.4 Intravitreal Injectable Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Intravitreal Injectable Players by Revenue
3.1.1 Global Top Intravitreal Injectable Players by Revenue (2021–2026)
3.1.2 Global Intravitreal Injectable Revenue Market Share by Players (2021–2026)
3.2 Global Top Intravitreal Injectable Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Intravitreal Injectable Revenue
3.4 Global Intravitreal Injectable Market Concentration Ratio
3.4.1 Global Intravitreal Injectable Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Intravitreal Injectable Revenue in 2025
3.5 Global Key Players of Intravitreal Injectable Head Offices and Areas Served
3.6 Global Key Players of Intravitreal Injectable, Products and Applications
3.7 Global Key Players of Intravitreal Injectable, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Intravitreal Injectable Breakdown Data by Drug
4.1 Global Intravitreal Injectable Historic Market Size by Drug (2021–2026)
4.2 Global Intravitreal Injectable Forecasted Market Size by Drug (2027–2032)
5 Intravitreal Injectable Breakdown Data by Disease
5.1 Global Intravitreal Injectable Historic Market Size by Disease (2021–2026)
5.2 Global Intravitreal Injectable Forecasted Market Size by Disease (2027–2032)
6 North America
6.1 North America Intravitreal Injectable Market Size (2021–2032)
6.2 North America Intravitreal Injectable Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Intravitreal Injectable Market Size by Country (2021–2026)
6.4 North America Intravitreal Injectable Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Intravitreal Injectable Market Size (2021–2032)
7.2 Europe Intravitreal Injectable Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Intravitreal Injectable Market Size by Country (2021–2026)
7.4 Europe Intravitreal Injectable Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Intravitreal Injectable Market Size (2021–2032)
8.2 Asia-Pacific Intravitreal Injectable Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Intravitreal Injectable Market Size by Region (2021–2026)
8.4 Asia-Pacific Intravitreal Injectable Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Intravitreal Injectable Market Size (2021–2032)
9.2 Latin America Intravitreal Injectable Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Intravitreal Injectable Market Size by Country (2021–2026)
9.4 Latin America Intravitreal Injectable Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Intravitreal Injectable Market Size (2021–2032)
10.2 Middle East & Africa Intravitreal Injectable Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Intravitreal Injectable Market Size by Country (2021–2026)
10.4 Middle East & Africa Intravitreal Injectable Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Regeneron Pharmaceuticals
11.1.1 Regeneron Pharmaceuticals Company Details
11.1.2 Regeneron Pharmaceuticals Business Overview
11.1.3 Regeneron Pharmaceuticals Intravitreal Injectable Introduction
11.1.4 Regeneron Pharmaceuticals Revenue in Intravitreal Injectable Business (2021–2026)
11.1.5 Regeneron Pharmaceuticals Recent Development
11.2 Bausch & Lomb
11.2.1 Bausch & Lomb Company Details
11.2.2 Bausch & Lomb Business Overview
11.2.3 Bausch & Lomb Intravitreal Injectable Introduction
11.2.4 Bausch & Lomb Revenue in Intravitreal Injectable Business (2021–2026)
11.2.5 Bausch & Lomb Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Intravitreal Injectable Introduction
11.3.4 Novartis Revenue in Intravitreal Injectable Business (2021–2026)
11.3.5 Novartis Recent Development
11.4 AbbVie (Allergan)
11.4.1 AbbVie (Allergan) Company Details
11.4.2 AbbVie (Allergan) Business Overview
11.4.3 AbbVie (Allergan) Intravitreal Injectable Introduction
11.4.4 AbbVie (Allergan) Revenue in Intravitreal Injectable Business (2021–2026)
11.4.5 AbbVie (Allergan) Recent Development
11.5 Alimera Sciences
11.5.1 Alimera Sciences Company Details
11.5.2 Alimera Sciences Business Overview
11.5.3 Alimera Sciences Intravitreal Injectable Introduction
11.5.4 Alimera Sciences Revenue in Intravitreal Injectable Business (2021–2026)
11.5.5 Alimera Sciences Recent Development
11.6 Roche
11.6.1 Roche Company Details
11.6.2 Roche Business Overview
11.6.3 Roche Intravitreal Injectable Introduction
11.6.4 Roche Revenue in Intravitreal Injectable Business (2021–2026)
11.6.5 Roche Recent Development
11.7 Bristol-Myers Squibb
11.7.1 Bristol-Myers Squibb Company Details
11.7.2 Bristol-Myers Squibb Business Overview
11.7.3 Bristol-Myers Squibb Intravitreal Injectable Introduction
11.7.4 Bristol-Myers Squibb Revenue in Intravitreal Injectable Business (2021–2026)
11.7.5 Bristol-Myers Squibb Recent Development
11.8 Bayer
11.8.1 Bayer Company Details
11.8.2 Bayer Business Overview
11.8.3 Bayer Intravitreal Injectable Introduction
11.8.4 Bayer Revenue in Intravitreal Injectable Business (2021–2026)
11.8.5 Bayer Recent Development
11.9 Bausch + Lomb
11.9.1 Bausch + Lomb Company Details
11.9.2 Bausch + Lomb Business Overview
11.9.3 Bausch + Lomb Intravitreal Injectable Introduction
11.9.4 Bausch + Lomb Revenue in Intravitreal Injectable Business (2021–2026)
11.9.5 Bausch + Lomb Recent Development
11.10 EyePoint Pharmaceuticals
11.10.1 EyePoint Pharmaceuticals Company Details
11.10.2 EyePoint Pharmaceuticals Business Overview
11.10.3 EyePoint Pharmaceuticals Intravitreal Injectable Introduction
11.10.4 EyePoint Pharmaceuticals Revenue in Intravitreal Injectable Business (2021–2026)
11.10.5 EyePoint Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Intravitreal Injectable Market Size Growth Rate by Drug (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Anti-VEGF Agents
Table 3. Key Players of Corticosteroids / Steroid Implants
Table 4. Key Players of Thrombolytic / Enzymatic Agents
Table 5. Key Players of Others
Table 6. Global Intravitreal Injectable Market Size Growth Rate by Formulation Type (US$ Million): 2021 vs 2025 vs 2032
Table 7. Key Players of Solution for Intravitreal Injection
Table 8. Key Players of Suspension for Intravitreal Injection
Table 9. Key Players of Others
Table 10. Global Intravitreal Injectable Market Size Growth Rate by Duration of Action (US$ Million): 2021 vs 2025 vs 2032
Table 11. Key Players of Short-acting (4–6 weeks)
Table 12. Key Players of Medium-acting (8–12 weeks)
Table 13. Key Players of Long-acting (> 6 months)
Table 14. Global Intravitreal Injectable Market Size Growth by Disease (US$ Million): 2021 vs 2025 vs 2032
Table 15. Global Intravitreal Injectable Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 16. Global Intravitreal Injectable Market Size by Region (US$ Million), 2021–2026
Table 17. Global Intravitreal Injectable Market Share by Region (2021–2026)
Table 18. Global Intravitreal Injectable Forecasted Market Size by Region (US$ Million), 2027–2032
Table 19. Global Intravitreal Injectable Market Share by Region (2027–2032)
Table 20. Intravitreal Injectable Market Trends
Table 21. Intravitreal Injectable Market Drivers
Table 22. Intravitreal Injectable Market Challenges
Table 23. Intravitreal Injectable Market Restraints
Table 24. Global Intravitreal Injectable Revenue by Players (US$ Million), 2021–2026
Table 25. Global Intravitreal Injectable Market Share by Players (2021–2026)
Table 26. Global Top Intravitreal Injectable Players by Tier (Tier 1, Tier 2, and Tier 3), based on Intravitreal Injectable Revenue, 2025
Table 27. Ranking of Global Top Intravitreal Injectable Companies by Revenue (US$ Million) in 2025
Table 28. Global 5 Largest Players Market Share by Intravitreal Injectable Revenue (CR5 and HHI), 2021–2026
Table 29. Global Key Players of Intravitreal Injectable, Headquarters and Area Served
Table 30. Global Key Players of Intravitreal Injectable, Products and Applications
Table 31. Global Key Players of Intravitreal Injectable, Date of General Availability (GA)
Table 32. Mergers and Acquisitions, Expansion Plans
Table 33. Global Intravitreal Injectable Market Size by Drug (US$ Million), 2021–2026
Table 34. Global Intravitreal Injectable Revenue Market Share by Drug (2021–2026)
Table 35. Global Intravitreal Injectable Forecasted Market Size by Drug (US$ Million), 2027–2032
Table 36. Global Intravitreal Injectable Revenue Market Share by Drug (2027–2032)
Table 37. Global Intravitreal Injectable Market Size by Disease (US$ Million), 2021–2026
Table 38. Global Intravitreal Injectable Revenue Market Share by Disease (2021–2026)
Table 39. Global Intravitreal Injectable Forecasted Market Size by Disease (US$ Million), 2027–2032
Table 40. Global Intravitreal Injectable Revenue Market Share by Disease (2027–2032)
Table 41. North America Intravitreal Injectable Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 42. North America Intravitreal Injectable Market Size by Country (US$ Million), 2021–2026
Table 43. North America Intravitreal Injectable Market Size by Country (US$ Million), 2027–2032
Table 44. Europe Intravitreal Injectable Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 45. Europe Intravitreal Injectable Market Size by Country (US$ Million), 2021–2026
Table 46. Europe Intravitreal Injectable Market Size by Country (US$ Million), 2027–2032
Table 47. Asia-Pacific Intravitreal Injectable Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 48. Asia-Pacific Intravitreal Injectable Market Size by Region (US$ Million), 2021–2026
Table 49. Asia-Pacific Intravitreal Injectable Market Size by Region (US$ Million), 2027–2032
Table 50. Latin America Intravitreal Injectable Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 51. Latin America Intravitreal Injectable Market Size by Country (US$ Million), 2021–2026
Table 52. Latin America Intravitreal Injectable Market Size by Country (US$ Million), 2027–2032
Table 53. Middle East & Africa Intravitreal Injectable Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 54. Middle East & Africa Intravitreal Injectable Market Size by Country (US$ Million), 2021–2026
Table 55. Middle East & Africa Intravitreal Injectable Market Size by Country (US$ Million), 2027–2032
Table 56. Regeneron Pharmaceuticals Company Details
Table 57. Regeneron Pharmaceuticals Business Overview
Table 58. Regeneron Pharmaceuticals Intravitreal Injectable Product
Table 59. Regeneron Pharmaceuticals Revenue in Intravitreal Injectable Business (US$ Million), 2021–2026
Table 60. Regeneron Pharmaceuticals Recent Development
Table 61. Bausch & Lomb Company Details
Table 62. Bausch & Lomb Business Overview
Table 63. Bausch & Lomb Intravitreal Injectable Product
Table 64. Bausch & Lomb Revenue in Intravitreal Injectable Business (US$ Million), 2021–2026
Table 65. Bausch & Lomb Recent Development
Table 66. Novartis Company Details
Table 67. Novartis Business Overview
Table 68. Novartis Intravitreal Injectable Product
Table 69. Novartis Revenue in Intravitreal Injectable Business (US$ Million), 2021–2026
Table 70. Novartis Recent Development
Table 71. AbbVie (Allergan) Company Details
Table 72. AbbVie (Allergan) Business Overview
Table 73. AbbVie (Allergan) Intravitreal Injectable Product
Table 74. AbbVie (Allergan) Revenue in Intravitreal Injectable Business (US$ Million), 2021–2026
Table 75. AbbVie (Allergan) Recent Development
Table 76. Alimera Sciences Company Details
Table 77. Alimera Sciences Business Overview
Table 78. Alimera Sciences Intravitreal Injectable Product
Table 79. Alimera Sciences Revenue in Intravitreal Injectable Business (US$ Million), 2021–2026
Table 80. Alimera Sciences Recent Development
Table 81. Roche Company Details
Table 82. Roche Business Overview
Table 83. Roche Intravitreal Injectable Product
Table 84. Roche Revenue in Intravitreal Injectable Business (US$ Million), 2021–2026
Table 85. Roche Recent Development
Table 86. Bristol-Myers Squibb Company Details
Table 87. Bristol-Myers Squibb Business Overview
Table 88. Bristol-Myers Squibb Intravitreal Injectable Product
Table 89. Bristol-Myers Squibb Revenue in Intravitreal Injectable Business (US$ Million), 2021–2026
Table 90. Bristol-Myers Squibb Recent Development
Table 91. Bayer Company Details
Table 92. Bayer Business Overview
Table 93. Bayer Intravitreal Injectable Product
Table 94. Bayer Revenue in Intravitreal Injectable Business (US$ Million), 2021–2026
Table 95. Bayer Recent Development
Table 96. Bausch + Lomb Company Details
Table 97. Bausch + Lomb Business Overview
Table 98. Bausch + Lomb Intravitreal Injectable Product
Table 99. Bausch + Lomb Revenue in Intravitreal Injectable Business (US$ Million), 2021–2026
Table 100. Bausch + Lomb Recent Development
Table 101. EyePoint Pharmaceuticals Company Details
Table 102. EyePoint Pharmaceuticals Business Overview
Table 103. EyePoint Pharmaceuticals Intravitreal Injectable Product
Table 104. EyePoint Pharmaceuticals Revenue in Intravitreal Injectable Business (US$ Million), 2021–2026
Table 105. EyePoint Pharmaceuticals Recent Development
Table 106. Research Programs/Design for This Report
Table 107. Key Data Information from Secondary Sources
Table 108. Key Data Information from Primary Sources
Table 109. Authors List of This Report
List of Figures
Figure 1. Intravitreal Injectable Picture
Figure 2. Global Intravitreal Injectable Market Size Comparison by Drug (US$ Million), 2021–2032
Figure 3. Global Intravitreal Injectable Market Share by Drug: 2025 vs 2032
Figure 4. Anti-VEGF Agents Features
Figure 5. Corticosteroids / Steroid Implants Features
Figure 6. Thrombolytic / Enzymatic Agents Features
Figure 7. Others Features
Figure 8. Global Intravitreal Injectable Market Size Comparison by Formulation Type (US$ Million), 2021–2032
Figure 9. Solution for Intravitreal Injection Features
Figure 10. Suspension for Intravitreal Injection Features
Figure 11. Others Features
Figure 12. Global Intravitreal Injectable Market Size Comparison by Duration of Action (US$ Million), 2021–2032
Figure 13. Short-acting (4–6 weeks) Features
Figure 14. Medium-acting (8–12 weeks) Features
Figure 15. Long-acting (> 6 months) Features
Figure 16. Global Intravitreal Injectable Market Size by Disease (US$ Million), 2021–2032
Figure 17. Global Intravitreal Injectable Market Share by Disease: 2025 vs 2032
Figure 18. Macular Degeneration Case Studies
Figure 19. Macular Edema Case Studies
Figure 20. Uveitis Case Studies
Figure 21. Retinal Vein Occlusion Case Studies
Figure 22. Others Case Studies
Figure 23. Intravitreal Injectable Report Years Considered
Figure 24. Global Intravitreal Injectable Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 25. Global Intravitreal Injectable Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 26. Global Intravitreal Injectable Market Share by Region: 2025 vs 2032
Figure 27. Global Intravitreal Injectable Market Share by Players in 2025
Figure 28. Global Intravitreal Injectable Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 29. The Top 10 and 5 Players Market Share by Intravitreal Injectable Revenue in 2025
Figure 30. North America Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. North America Intravitreal Injectable Market Share by Country (2021–2032)
Figure 32. United States Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Canada Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Europe Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Europe Intravitreal Injectable Market Share by Country (2021–2032)
Figure 36. Germany Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. France Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. U.K. Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Italy Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Russia Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Ireland Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Asia-Pacific Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Asia-Pacific Intravitreal Injectable Market Share by Region (2021–2032)
Figure 44. China Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Japan Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. South Korea Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Southeast Asia Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. India Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Australia & New Zealand Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 50. Latin America Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 51. Latin America Intravitreal Injectable Market Share by Country (2021–2032)
Figure 52. Mexico Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 53. Brazil Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 54. Middle East & Africa Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 55. Middle East & Africa Intravitreal Injectable Market Share by Country (2021–2032)
Figure 56. Israel Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 57. Saudi Arabia Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 58. UAE Intravitreal Injectable Market Size YoY Growth (US$ Million), 2021–2032
Figure 59. Regeneron Pharmaceuticals Revenue Growth Rate in Intravitreal Injectable Business (2021–2026)
Figure 60. Bausch & Lomb Revenue Growth Rate in Intravitreal Injectable Business (2021–2026)
Figure 61. Novartis Revenue Growth Rate in Intravitreal Injectable Business (2021–2026)
Figure 62. AbbVie (Allergan) Revenue Growth Rate in Intravitreal Injectable Business (2021–2026)
Figure 63. Alimera Sciences Revenue Growth Rate in Intravitreal Injectable Business (2021–2026)
Figure 64. Roche Revenue Growth Rate in Intravitreal Injectable Business (2021–2026)
Figure 65. Bristol-Myers Squibb Revenue Growth Rate in Intravitreal Injectable Business (2021–2026)
Figure 66. Bayer Revenue Growth Rate in Intravitreal Injectable Business (2021–2026)
Figure 67. Bausch + Lomb Revenue Growth Rate in Intravitreal Injectable Business (2021–2026)
Figure 68. EyePoint Pharmaceuticals Revenue Growth Rate in Intravitreal Injectable Business (2021–2026)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
